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Abstract: We report a case of refractory idiopathic childhood pyoderma gangrenosum in a
young boywho had suffered from this disease since 3 years of age. He had unfavorable responses
and intermittent relapses under different combinations of cytotoxic and steroid therapies.
Although there was not much information available about inﬂiximab use for biologic and
childhood pyoderma gangrenosum, eventually we decided to use inﬂiximab in this patient.
Inﬂiximab showed a dramatic response and resulted in full recovery during 2 years' follow-up.
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Introduction
Pyoderma gangrenosum (PG) is an uncommon neutrophilic dermatosis in children
(4% of cases). Despite its unknown pathogenesis, it may be associated with a
variety of diseases, mainly ulcerative colitis, Crohn's disease, and hematologic
malignancies.1 Isolated cases have been described in infants and childrens.1,2 It
has chronic characteristic features, and can be accompanied by severe anemia,
leading to difﬁcult diagnosis.3,4 Most children with PG have been successfully
treated with oral corticosteroids. We report a case in its ulcerative form and
refractory to all known therapies, steroids, and cytotoxic drugs. Our study was
complaint with the Helsinki Declaration and approved by the ethics committee of a
faculty of medicine. Informed consent was obtained from the patient's parents.
Case report
The patient is now an 18-year-old. He was referred at 3 years of age with a
complaint of a chronic wound in the medial region of the right thigh and systemic
symptoms, including lethargy, weight loss, and intermittent fever since 2 months
prior. The lesion was initially a small red ulcer, which rapidly progressed in size
with yellowish nonpurulent bloody discharge. Initially, the patient was hospitalized
and treated with topical and systemic antibiotics. Blood studies for systemic
vasculitis and chronic granulomatous disease and all investigations to rule out
any background conditions, such as inﬂammatory bowel disease, were normal.
His skin lesion improved with local care and topical antibiotic for 2 months, and
the patient was discharged without any speciﬁc diagnosis. However, after a few
months he found new lesions on his right hand and abdomen. Biopsy of the lesions
showed subacute necrotic dermatitis, and then prednisolone and azathioprine were
started. Several months later, when his medications were tapering, a new lesion of
15×15 cm developed in the left thigh, and this time the patient was diagnosed with
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PG, based on the second biopsy. Reevaluation of the
patient for systemic vasculitis and inﬂammatory bowel
disease again were negative. With a ﬁnal diagnosis of
PG, he received cyclosporine and dapsone. However,
despite treatment with these medications for consecutive
years, he suffered a recurrent and relapsing course. We
also tried different combination therapies, such as metho-
trexate, cyclophosphamide, and mycophenolate mofetil,
for several courses, with unfavorable responses. Based
on an unpublished report by Göknur Kalkan on the asso-
ciation of familial Mediterranean fever and PG in the
Mediterranean area, we assessed MEFV gene mutations,
which showed normal results. Because of refractory
courses with different relapses and temporary recoveries,
we decided to start inﬂiximab as a biologic drug at 100 mg
at weeks 0, 2 and 6 and then every 4 weeks. He showed
dramatic clinical improvement in a few months, without
any known side effects over the previous 2 years. There
was not any recurrence, and all previous medications were
discontinued. During 2 years; follow-up at the rheumatol-
ogy clinic, he achieved full recovery.
Discussion
We report an idiopathic childhood refractory PG based on
typical primitive sterile ulcerations and histological results
that did not show any response to previously known med-
ications. Despite advances in medical therapy, the outlook
for PG is unpredictable. Delayed diagnosis or misdiagno-
sis of PG will certainly lead to exacerbation and progres-
sion of the disease. However, close and prolonged
monitoring is necessary in these patients. The etiopatho-
genesis of PG is poorly known. Prognosis is usually good
with corticosteroid therapy, and in steroid-resistant cases
some authors have recommended immunosuppressive
drugs.4,5 Systemic therapy is the mainstay of treatment
for rapidly progressive PG. Corticosteroids, such as pre-
dnisolone, are initially used to prevent progression and
restrain the inﬂammatory process. Combinations of steroid
and cytotoxic drugs, such as azathioprine, cyclophospha-
mide, cyclosporine, or mycophenolate mofetil, are used in
patients with steroid-resistant disease or as a steroid-spar-
ing measure.5,6 Under different combinations, our patient
had periods of relapse and refractory courses, and thus we
decided to start inﬂiximab based on the diagnosis of idio-
pathic childhood refractory PG. A monoclonal antibody
against TNF, inﬂiximab has been a particularly effective
medication in treatment of PG associated with inﬂamma-
tory bowel disease.7 There are recent data about new
approaches and treatment of PG with tacrolimus,8 differ-
ent biologics and immunoglobulins,9 and a combination of
two drugs (tofacitinib and inﬂiximab);10 however, all
these studies were in adult patients, and experience in
childhood PG is limited. In children with idiopathic PG,
there has been very limited experience with biologic ther-
apy, and our study is by far one of the most effective trials
of a biologic in childhood refractory PG. Our results
showed that inﬂiximab is a promising treatment in refrac-
tory idiopathic PG.
Conclusion
Inﬂiximab seems to be an effective biologic treatment in
idiopathic refractory childhood PG.
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